Actively Recruiting
Study of CT1195E CAR-T Cell Treatment for Adults With Refractory or Progressive Systemic Sclerosis and Lung Involvement
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-01-21
12
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, and cellular metabolic activity of CT1195E CAR-T cell therapy in patients with refractory or progressive systemic sclerosis SSc. This early phase 1 clinical study includes a dose escalation phase followed by a dose expansion phase to explore the best dose levels and treatment effects in patients with this condition lasting up to 7 years and complicated by interstitial pneumonia. Participants receive an infusion of CT1195E cells during the study. The trial is a single-arm, open-label study without a placebo group. The dose escalation phase determines the maximum tolerated dose and the dose range, while the dose expansion phase further evaluates the therapy at those doses. Treatment effects and safety are monitored closely after infusion. Participants will undergo various assessments at multiple time points baseline, 1st, 2nd, 3rd, 6th, 9th, and 12th months post-treatment. These include clinical scores for systemic sclerosis, lung and cardiac function tests, skin elasticity measurements, antibody level monitoring, and inflammation markers. Safety is monitored intensively for up to 180 days after infusion, including adverse events and dose-limiting toxicities. The presence and duration of CT1195E cells in blood are tracked for up to 1 year, and participants are observed for up to 12 months in total.
CONDITIONS
Brief Title
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
Research Team
Q
Qiubai Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here